Travere Shares Rise 8.4%; Co. To Cut Staff, Focus on IgAN, HCU Treatments
By Stephen Nakrosis
Shares of Travere Therapeutics were trading higher in Monday's after-hours market, following new the company plans to reduce its workforce by about 20% and focus near-term resources on its ongoing Filspari launch in IgAN and the advancement of pegtibatinase in classical HCU.
The move will extend the company's expected cash runway into 2028, it said.
Travere's stock rose 8.4% to $6.82 after hours. The stock closed the day's regular session at $6.29, losing just over 2%, and was down 70% this year through Monday's close.
Travere said it completed a successful pre-NDA meeting with the U.S. food and Drug Administration for Filspari in IgAN, or Immunoglobulin A Nephropathy, a kidney disease also known as Berger's disease.
Travere also said it will focus on advancing pegtibatinase in classical HCU, also known as homocystinuria due to CBS deficiency, a disorder that can lead to the buildup of certain amino acids in the blood.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
December 04, 2023 16:59 ET (21:59 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks